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Abstract Interaction of IL-10 with its receptor leads to the 
activation of STAT transcription factors. Herein we report the 
IL-10 dependent simultaneous activation of three STAT 
transcription factors: Statl, Stat3, and StatS. Upon IL-10 
treatment multiple Stat proteins become simultaneously acti- 
vated, and bind to different promoters with equal kinetics but 
form distinct homo- and heterodimeric transcriptionally active 
complexes depending on the STAT-conscnsus elements of a 
selected gene promoter. Upon IL-10 treatment Statl, 3, and 5 
bind to the GRR of the Fc~RI gene, activated Statl and 3 bind to 
the SIE sequence of the c-fos promoter and transcriptionally 
active Stat5 assembles at the PRL-STAT consensus equence of 
the [l-casein gene. Thus, functionally relevant STAT dimeriza- 
tion is influenced by the activated cytokine receptor as well as the 
specific STAT consensus equence present in a specific gene 
promoter. 
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1. Introduction 
Recent studies demonstrated that multiple cytokines ignal 
through activation of a novel family of transcription factors, 
termed STAT proteins [1,2]. To date, eight proteins have been 
identified belonging to the family of STAT transcription fac- 
tors [3]. STAT activation is mediated by the interaction of 
these transcription factors at distinct sites of a cytokine recep- 
tor's intracellular domain and by the subsequent tyrosine and 
serine/threonine phosphorylation of the STAT proteins [4,5]. 
Phosphorylation of the STAT transcription factors is a func- 
tion of the tyrosine kinase activity of a cytokine receptor itself 
and/or receptor associated Janus-kinases and serine/threonine 
phosphorylation has been shown to be mediated by members 
of the MAP-kinase family [6-9]. STAT proteins that are acti- 
vated in the cytoplasm of a cytokine treated cell translocate to 
the nucleus and display DNA binding activity at the promo- 
ters of diverse genes forming homo- or heterodimeric com- 
plexes [7]. Taking into consideration that cytokines that serve 
opposite functions can activate one STAT protein, we sought 
to investigate further the role of STAT transcription factors in 
the signaling pathway that is initiated by a pleiotropic yto- 
kine like IL-10 [10]. A recent report by Finbloom and Wine- 
stock [11] demonstrated the IL-10 dependent activation of 
Statl and Stat3 in human T-cells and monocytes. The results 
*Corresponding author. Fax: (49) (761) 270 7177; 
Email: Nordt@mml 1 .ukl.uni-freiburg.de 
0014-5793/96/$12.00 © 1996 Federation of European Biochemical Societies. 
PH S00 1 4- 579 3(96)00990-8  
presented herein extend the initial studies of IL-10 dependent 
STAT activation and demonstrate that, in addition to Statl 
and Stat3, Stat5 becomes tyrosine phosphorylated by IL-10. 
IL-10 dependent signaling is shown to involve the tyrosine 
phosphorylation of multiple STAT proteins and IL-10 de- 
pendent transcriptional gene activation has been found to 
depend on specific STAT homo- and heterodimers that are 
recruited at the site of a specific promoter egion. 
2. Materials and methods 
2.1. Reagents 
IL-10 and IFN7 were purchased from Genzyme (Cambridge, MA), 
IL-3 was from Boehringer Mannheim, Germany. Streptavidin-Sephar- 
ose was obtained from Sigma (St. Louis, MO, USA). Horseradish- 
peroxidase-conjugated goat-anti-rabbit IgG was purchased from 
Amersham (Arlington Heights, IL, USA). Polyclonal antisera specific 
for Statl Stat4 were generously provided by Dr. J. Darnell, Rock- 
efeller University, New York, NY, USA. Stat5 specific antisera were 
prepared as described [12]. Stat6 specific antisera was generously pro- 
vided by Dr. S. McKnight, Tularic Inc., Palo Alto, CA. 
2.2. Cells 
IL-3 dependent murine preB-cells BaF3 lacking the mlL-10 recep- 
tor and BaMR cells (BaF3 stably transfected with the raiL-10 recep- 
tor) were cultured as described [13,14]. 
2.3. Oligonucleotides 
An 18 base pair oligonucleotide probe GRR of the Fc~RI gene 
promoter (sense strand, 5'-ATGTATT'I'CCCAGAAA; antisense 
strand, 5'-CTTTTCTGGGAAATA), the PRL STAT consensus ele- 
ment of the [~-casein gene promoter (sense, 5'-AGATTTCTAG- 
GAATTCAAATCCAC; antisense, 5'-GTGGATTTGAATTCCTA- 
GAAATCT) [14], and the SIE of the c-fos promoter (sense, 5'- 
GTCGACAGTTCCCGTCAATC; antisense, 5'-GATTGACGG- 
GAACTGTCGAC) were made by annealing the oligonucleotides as 
described [14,16]. Precipitation studies were performed using biotinyl- 
ated GRR oligonucleotide that was immobilized on a streptavidin- 
agarose matrix (Sigma, St. Louis, USA). 
2.4. Electromobility shift assay (EMSA) 
Cells were harvested at distinct ime points, nuclear extracts pre- 
pared and gel shift experiments performed as described [14]. 
2.5. STA T protein precipitation 
1 ng of biotinylated GRR probe was coupled to 100 gl of strepta- 
vidin-Sepharose for 30 min at 4°C. Sepharose was washed in PBS and 
incubated with 1 ml of nuclear extracts derived from 7 x 107 BaMR 
cells treated for 10 min at 37°C with 100 ng/ml rmlL-10, 100 ng/ml 
rmlL-3 or 100 ng/ml rmlFNy. After 2 h incubation the Sepharose was 
pelleted at 100 × g for 5 min and washed with 800 pl of washing buffer 
(50 mM Tris-HC1, pH 8.0, 150 mM NaCI, 0.5% NP-40, 10% glycerol, 
1 mM EDTA, 1 mM Na-orthovanadate, 10 mM NaF, 750 gM DTT, 
1 mM PMSF) and 10 gg/ml leupeptin and aprotinin. The Sepharose 
was resuspended in 50 pl 2 x Laemmli buffer and 180 mM 2-mercap- 
All rights reserved. 
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Fig. 1. IL-10 induces the DNA binding activity of distinct STAT proteins in the STAT consensus elements of the Fc),RI, the ~-casein, and the 
c-fos promoters. Nuclear extracts from IL-10, |L-3 or IFN 7 treated BaMR cells were assayed by gel-shift analyses employing 25 000 cpm (1 ng) 
of the GRR, PRL or SIE probes, respectively (left panels). Competition studies were performed by incubating 1 ng of the radiolabeled GRR 
probe with 3 lag of nuclear extracts derived from IL-10 treated cells in the presence of a 100-fold excess of the unlabeled GRR probe, the PRL 
or SIE probes (right panel). DNA binding activity was assayed by polyacrylamide electrophoresis and autoradiography. 
toethanol (Sigma) and the suspension was heated to 70°C for 5 min. 
Samples were subjected to SDS-PAGE. Proteins were transferred to 
nitrocellulose membranes (BioRad Laboratories, Richmond, CA) and 
membranes were blocked for 18 h at 4°C with 50 mM Tris-buffered 
physiologic saline pH 8.0 (TBS) containing 2% BSA (Sigma) and 0.5% 
Tween 20 (TBST) (BioRad). Membranes were washed in TBST, in- 
cubated with STAT specific antisera t 1:3000 final dilution for 1 h, 
washed, incubated with HRPO-conjugated goat-anti-rabbit-IgG at
1:7500 for 20 min and developed by chemiluminescence using the 
ECL detection reagent (Amersham, Arlington Heights, IL). 
2.6. Transient ransfection assays 
The pXM-PRL(-105) vector that contained 105 bp upstream the 
transcriptional start site of the 13-casein promoter or a mutated ver- 
sion of that sequence were used as described [2]. 5x 10 6 BaMR cells 
were transiently transfected by electroporation with 10 ~g of the 
pXM-PRL(-105)/(mut) vectors, respectively, and 1 ~g of a CMV- 
CAT-reporter construct [15,16]. 24 h later BaMR cells were either 
left untreated, or treated with 100 ng/ml IL-3 or IL-10 for 48 h. Cells 
were harvested and luciferase assays were performed as described [17]. 
CAT assays were performed using the Boehringer Mannheim ELISA 
system. Data are presented as the mean of triplicate determinations of 
relative light units (RLU) normalized for transfection efficiency by 
CMV-CAT reporter construct. Each experiment was repeated at least 
three times. 
3. Results 
3.1. IL-IO treatment of  BaMR cells leads to the activation of  
multiple STAT  proteins 
To test for STAT activation gel-shift experiments were per- 
formed. IL-10 treatment of IL-10 receptor bearing BaMR 
cells led to the generation of three distinct DNA binding 
complexes in the GRR of the FcTRI promoter, to the genera- 
tion of a single gel-shift complex with the PRL probe of the [3- 
casein promoter and to the formation of three DNA binding 
complexes with the SIE probe of the c-fos promoter (Fig. 1). 
The latter complexes howed slightly higher mobilities and 
significantly reduced binding affinities compared to the IL- 
l0 induced GRR binding gel shift complexes (Fig. 1). To 
check that the difference in the binding affinities was not 
caused by the amount of nuclear proteins or the radioactivity 
of the EMSA probes used, 3 ~g of nuclear extracts were in- 
cubated with 25 000 cpm (1 ng). Further control experiments 
using IL-3 or IFN~( treated BaMR cells demonstrated single 
IL-3 induced DNA complexes with comparable binding affin- 
ities in the GRR and the PRL probe. In addition, a Statl-like 
gel shift complex was observed when the IL-3 treated BaMR 
extracts were probed with the SIE sequence. In nuclear ex- 
tracts from IFN 7 stimulated BaMR cells, one prominent gel 
shift band was obtained with the GRR probe, no DNA com- 
plex was formed with the PRL probe and a DNA complex 
with reduced binding intensity was obtained with the S1E 
probe (Fig. 1, left panels). In summary, IL-3 and IFN 7 treat- 
ment of the cells leads to the formation of single DNA bind- 
ing complexes in the GRR,  PRL, SIE or the GRR and S1E 
consensus equences, respectively. In contrast, IL-10 induced 
the combinatorial formation of multiple gel shift complexes 
depending on the STAT consensus probes used. To identify 
further the binding characteristics of the IL-10 induced com- 
plexes competition experiments were performed. Therefore, 
nuclear extracts from IL-10 treated cells were preincubated 
with a 100-fold excess of unlabeled GRR,  PRL or SIE probe 
and EMSA complexes were detected thereafter by probing 
with 1 ng of the radiolabeled GRR probe (Fig. 1, right panel). 
Unlabeled GRR probe competed the binding of the IL-10 
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Fig. 2. IL-10 activates the DNA binding of multiple STAT proteins. Supershift experiments were performed employing 3 ~tg of nuclear extracts 
derived from IL-10 (100 ng/ml) treated cells in the presence of normal rabbit sera or STAT specific antisera using the GRR or PRL probes, re- 
spectively. 
dependent DNA complexes indicating the specificity of the 
DNA-protein interaction (Fig. 1, right panel, lanes 2,3). An 
excess of the PRL probe only slightly reduced the intensity of 
the upper band A whereas preincubation of the nuclear ex- 
tracts with a 100-fold excess of the SIE probe competed the 
binding of the lower band C, the middle band B and competi- 
tion with unlabeled SIE probe reduced the intensity of the IL- 
l0 induced GRR complex A (Fig. 1, right panel). These re- 
sults indicated that multiple STAT proteins were activated in 
the nuclei of IL-10 treated cells that diversely bound to STAT 
consensus elements within the selected promoter sequences. 
To investigate the time characteristics of IL-10 induced gel 
shift complexes nuclear extracts were harvested at distinct 
time points and probed using the GRR or PRL probes, re- 
spectively. IL-10 induced gel shift complexes were first detect- 
able after 1 min, were maximal after 7 to 30 min and disap- 
peared after 120 rain upon addition of IL-10. No differences 
in the IL-10 dependent kinetics were observed with regard to 
the binding characteristics to either one of the probes used 
and equal results were obtained with the SIE probe (data not 
shown). In contrast, IL-3 induced STAT activation was ob- 
served after 1 min and was maintained at maximal evels for 
more than 120 min up to a maximum of 4-5 h after addition 
of IL-3 (data not shown). Thus, IL-10 induced activation of 
STAT proteins in a very time-restricted manner whereas IL-3 
dependent STAT activation was extended to as long as 4-5 h 
after cytokine treatment of the cells. 
3.2. IL-IO activates the DNA binding of Statl, Stat3, and 
Stat5 
To identify the nature of the STAT proteins that were acti- 
vated in response to IL-10, supershift experiments were per- 
formed that employed STAT specific antisera. Stat2, Star4, 
and Stat6 specific antisera did not influence the formation 
of the IL-10 dependent EMSA complexes (data not shown) 
as did normal rabbit serum (Fig. 2). However, when the GRR 
sequence was used Statl specific antisera supershifted the low- 
est band C and reduced the intensity of the middle band B, 
Stat3 specific antisera supershifted the middle band B and 
reduced the intensity of the upper band A, and Stat5 specific 
antisera partially supershifted the upper band A of the EMSA 
complexes (Fig. 2, left panel). The activation of multiple 
STAT proteins by IL-10 was confirmed by the precipitation 
of phosphorylated forms of Statl, Stat3, and Stat5 using Se- 
pharose-coupled biotinylated ouble-stranded GRR probe 
(Fig. 3). Control experiments on the activation of Statl and 
Stat5 were performed using IFNT or IL-3 treated nuclear ex- 
tracts, respectively (Fig. 3). Despite the herein documented 
simultaneous activation of multiple STAT proteins upon IL- 
l0 treatment of the cells, only Stat5 antisera supershifted the 
EMSA complex that was formed in the PRL sequence of the 
~-casein promoter (Fig. 2, right panel). Statl and Stat3 anti- 
sera supershifted the complexes obtained with the SIE se- 
quence (data not shown). Thus, these data demonstrate the 
simultaneous activation of multiple STAT proteins by the 
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Fig. 3. IL-10 activates the nuclear translocation and DNA binding activity of Statl, 3, and 5 to the GRR of the FcTRI gene. Nuclear extracts 
from IL-10, IL-3 or IFNy treated BaMR cells were precipitated with Sepharose-coupled biotinylated GRR double stranded oligonucleotide. 
Proteins were separated by SDS-gel electrophoresis, Western-blotted and probed with Statl, Star3, and Stats specific antisera, respectively. 
activated IL-10 receptor but further indicate the differential 
recruitment of these transcription factors at the sites of the 
specific promoters. 
3.3. Statl and Stat5 do not form heterodimers 
To further investigate he characteristics of the binding spe- 
cificities and the nature of the heterodimer formation of 
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Fig. 4. Simultaneous activation of Statl and Stat5 does not lead to 
heterodimer formation. BaMR cells were treated with 100 ng/ml IL- 
l0, 100 ng/ml IL-3, 10 ng/ml IFN 7 or a combination of IL-3 and 
IFNy. Nuclear extracts were probed for the presence of STAT 
DNA-binding activity by gel shift analyses using the GRR (left pan- 
el) or the PRL probe (right panel), respectively. 
STAT proteins, BaMR cells were treated with IL-3 and 
IFNy individually or in combination or with IL-10. IL-10 
activated the expected trimeric gel shift complex at the 
GRR site (Fig. 4, left, first lane). A single IL-10 induced gel 
shift band containing Stat5 was observed when nuclear ex- 
tracts were probed with the PRL oligonucleotide (Fig. 4, 
right, first lane). Stat5 that became activated upon IL-3 treat- 
ment of the BaMR cells displayed binding affinity to the GRR 
as well as to the PRL oligonucleotide (Fig. 4, left and right, 
second lanes). Upon IFNy treatment of the BaMR cells a gel 
shift complex containing Statl homodimers was induced as 
described that bound to GRR but not to the PRL sequence 
(Fig. 4, left and right, third lanes) [1]. To test further for 
heterodimer formation of Statl and 5, BaMR cells were si- 
multaneously treated with IL-3 and IFNy. When nuclear ex- 
tracts of these BaMR cells were probed for DNA binding 
complexes by EMSA, two distinct gel shift bands to the 
GRR oligonucleotide were observed. In contrast, a single 
STAT complex was observed with the PRL sequence. Thus, 
the simultaneous treatment of BaMR cells with IL-3 and 
IFNy led to the simultaneous activation of Statl and 5 that 
both bound in the promoter of the F~RI  gene. However, a 
third complex consisting of Statl/Stat5 heterodimers was not 
formed independent of the ratio of activated Stat5 to Statl 
used in the assay (data not shown). Thus, these experiments 
indicated that simultaneous Statl/Stat5 activation does not 
lead to the formation of Statl/Stat5 heterocomplexes. 
3.4. IL-IO dependent STATprotein activation leads to the 
recruitment of transcriptionally active Stat5 protein at the 
promoter of the B-casein gene 
Our data have demonstrated that multiple STAT proteins 
(Statl, 3, and 5) become activated by IL-10. However, of the 
IL-10 induced STAT proteins only Stat5 binds in the promo- 
ter of the 13-casein gene. We next addressed the question of 
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Fig. 5. IL-10 regulates the transcriptional activity of the [3-casein promoter through the activation of Stat5. BaMR cells were transiently trans- 
fected with the pXM-PRL(--105) luciferase reporter construct, cells were treated with IL-10 (100 ng/ml) or IL-3 (100 ng/ml) and luciferase as- 
says were performed after 48 h (middle bars). In control experiments ransfected BaMR cells were left untreated (left bars) and basal activity 
of the construct was determined. To control for specificity, a reporter construct pXM-PRL(-105)mut mutated at the site of the PRL-STAT 
consensus element of the [3-casein promoter was transiently transfected into BaMR cells and cells were treated as before (right bars). Arbitrary 
units are luciferase activity units normalized to CAT activity to account for differences in transfection efficiencies. 
whether the IL-10 dependent recruitment of the Stat5 protein 
in the [3-casein promoter was sufficient for transcriptional c- 
tivation. Therefore, reporter constructs panning the proximal 
part of the [3-casein promoter 105 bp upstream of the tran- 
scriptional start site encompassing the Star5 consensus e- 
quence were transiently transfected into BaMR cells. Trans- 
fected cells were subsequently treated with IL-10 and IL-3, 
respectively, and luciferase activity was measured. These ex- 
periments revealed that the Star5 consensus equence in the 
proximal [3-casein promoter was sufficient o transcriptionally 
activate the luciferase gene in response to IL-10 (Fig. 5). The 
transcriptional ctivation was specific for the Stat5 consensus 
sequence because a single base pair mutation within that se- 
quence ablated not only IL-3 induced Star5 activation but 
also the IL-10 induced transcriptional ctivation of the repor- 
ter gene (Fig. 5). Control experiments were performed in 
BaMR cells that were transfected with the luciferase construct 
but left untreated. In these cells no basal activity of the con- 
struct was obtained (Fig. 5). Luciferase activity was normal- 
ized to CAT activity to account for differences in transfection 
efficiencies of the cells. Thus, the binding of Stat5 in the pro- 
moter of the [3-casein gene was sufficient o activate an IL-10 
dependent transcriptional response. In summary, IL-10 acti- 
vates multiple STAT proteins in IL-10 responsive cells. These 
activated STAT proteins bind in the promoters of distinct 
genes and become transcriptionally active in a combinatorial 
manner. 
4. Discussion 
4.1. Statl, Stat3, and Stat5 activation by 1L-IO 
While IL-10 is known to transduce its pleiotropic functions 
on cells of the immune system [10] by interacting with a spe- 
cific IL-10 receptor that belongs to the interferon receptor 
family [13], little data exist that characterize IL-10's intracel- 
lular signalling on a molecular basis [18,19]. A recent report 
by Finbloom and Winestock [11] demonstrated the activation 
of Statl and 3 through IL-10. Here, we extend these data by 
showing that a third STAT protein Star5 is activated by IL-10 
in addition to Statl and 3. STAT proteins are known to bind 
in the promoters of genes by forming homo- or heterodimers 
[20,21]. One cytokine may thus activate one STAT protein like 
IFNT, prolactin, erythropoietin (EPO), thrombopoietin 
(TPO), IL-4, IL-5 [19,22,23] or one cytokine may activate 
two STAT transcription factors like IL-3, IL-6, CNTF, 
OSM, LIF [24]. Here we first demonstrate that multiple 
STAT transcription factors become activated by a single cy- 
tokine, IL-10. Statl, Star3, and Star5 simultaneously activated 
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by 1L-10 subsequently form multiple STAT heterocomplexes 
(Statl-Stat3 and Stat3-Stat5) that are detectable depending on 
the STAT consensus equence used. However, the simulta- 
neous activation of Statl and Stat5 upon treatment with IL- 
l0 or upon combined treatment of BaMR cells with IFNy and 
IL-3 did not lead to Statl/Stat5 heterocomplex formation. 
Thus, the simultaneous tyrosine phosphorylation f different 
STAT proteins appears as a prerequisite but does not neces- 
sarily lead to the formation of STAT heterocomplexes. Our 
previous tudies of the IL-10 receptor signalling pathway sug- 
gested a direct assembly of Stat3 at specific phosphotyrosine 
containing sequences YXXQ within the intracellular domain 
of the IL-10 receptor's s-chain [26]. Our current data indicate 
the IL-10 dependent activation of multiple STAT proteins 
that form hetero- or homodimers at the sites of different pro- 
moters in a combinatorial manner. Thus, two possible mech- 
anisms of STAT dimerization might be discussed. First, 
upon STAT activation all possible STAT-dimer combinations 
could be randomly formed at the intracellular parts of the 
cytokine receptors, translocated to the nucleus and recruited 
at the different STAT consensus elements. To date, our data 
so far do not support his hypothesis. Second, STAT proteins 
could be activated at the receptor's intracellular domain and 
STAT dimerization could specifically be rearranged in the 
nucleus depending on the promoter sites. Heterodimer forma- 
tion of STAT proteins might thus be influenced by the struc- 
ture or the activation mode of the molecules [21]. Specific 
tyrosine residues of Statl (Y701) and Stat5 (Y694) have 
been identified that are necessary for transcriptional ctivity 
[2,21]. These tyrosine residues are known to be important for 
the formation of STAT homo- and heterodimers [1,21]. In 
addition, modulation of the DNA binding activity of the 
STAT proteins Statl and Stat3 is mediated through the ser- 
ine/threonine phosphorylation within their carboxy-terminal 
part [8,9]. Thus, specificity of the STAT signaling events 
may subsequently bemediated through different mechanisms: 
(1) the potential of a cytokine's receptor intracellular domain 
to recruit distinct STAT proteins [20]; (2) the expression of 
specific STAT proteins in a cell [3]; (3) the activation of sig- 
naling cascades other than the JAK-pathway [23,25,26]; and 
(4) the STAT consensus sequence presented by a specific gene 
promoter [27]. Thus, specificity and selectivity in STAT de- 
pendent signal transduction appear to be achieved in a multi- 
factorial and combinatorial manner. 
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